knee osteoartritis
Conditions
Interventions
Group A:2 units of Suling were administered 15-20 minutes before surgery and completed before the operation began. Method of administration: slow intravenous infusion no less than 3min. 1g tranexamic
Group B:Tranexamic acid injection was administered intravenously at the rate of 40mg/kg 15-20 minutes before surgery. The first administration was completed before surgery. 1g tranexamic acid was inje
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years, no gender limit; 2. Patients with knee osteoarthritis who have surgical indications and indications of total knee replacement and need to undergo primary unilateral total knee replacement; 3. Voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of deep vein thrombosis, arterial thrombosis, cardio-cerebrovascular thrombosis or infarction, or pulmonary embolism within the last 6 months; 2. Preoperative color Doppler ultrasonography of lower limbs showed thrombus formation in popliteal vein and its proximal vein, or significant stenosis in lower limb atherosclerosis; 3. Allergic constitution: allergic to dextran, tranexamic acid, sulin and anticoagulants; 4. Patients with coagulation dysfunction; 5. Patients with dual antiplatelet therapy that cannot be replaced; 6. Patients diagnosed with coronary atherosclerotic heart disease or AHA cardiac function grade ?; 7. Patients with previous or present history of malignant tumor; 8. ASA grade ? or above; 9. Patients with systolic blood pressure > 160mmHg or diastolic blood pressure > 100mmHg; 10. Patients with severe impairment of liver and kidney function before surgery; 11. A female patient or a male patient's spouse planning to become pregnant, pregnant and lactating; 12. Participate in other clinical studies 3 months before surgery or during the study; 13. Patients with mental illness and uncooperative patients; 14. Patients considered by the investigators to be unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total operative blood loss; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraoperative blood loss;Coagulation function;Incidence of arteriovenous thrombosis of both lower limbs;Incision healing;Blood transfusion rate;Blood transfusion volume;Visual Analogue Scale Score;American Hospital for Special Surgery Knee Score;Blood and fluid oozing from the wound; | — |
Countries
China
Contacts
Public ContactPei Fuxing
West China Hospital, Sichuan University
Outcome results
None listed